Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Autor(es):Mostrar menos -

Russo, Momtchilo ; Mendes-Correa, Maria Cassia ; Lins, Bruna B. ; Kersten, Victor ; Pernambuco, Paulo C. A. ; Martins, Toni Ricardo ; Tozetto-Mendoza, Tania Regina ; Boas, Lucy Santos Vilas ; Gomes, Brisa Moreira ; Dati, Livia Mendonca Munhoz ; Duarte-Neto, Amaro Nunes ; Reigado, Gustavo Roncoli ; Frederico, Ana Beatriz T. ; Cunha, Danielle R. de A. ; de Paula, Anderson Vicente ; da Silva, Jose Igor G. ; Vasconcelos, Carlos F. Moreira ; Chambergo, Felipe S. ; Nunes, Viviane Abreu ; Bom, Ana Paula Dinis Ano ; Castilho, Leda R. ; Martins, Rodrigo A. P. ; Hirata, Mario Hiroyuki ; Mirotti, Luciana ; Tripp, Ralph A.

• Tipo de documento: Artigo Científico
• Fonte: VACCINES; v. 11, n. 11, p. 17-pg., 2023-11-01.

Resumo

Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity. (AU)

• Processo FAPESP: 21/12502-7 - Modelo experimental prototípico de imunoterapia transdermal com proteínas recombinantes para asma alérgica
• Beneficiário: Momtchilo Russo
• Modalidade de apoio: Auxílio à Pesquisa - Regular